H1 2025 Financial Results
Access all the information about Grifols' H1 Financial Results.
Showing 234 search results
Grifols Reports 7% Revenue Growth to EUR 3,677m and Net profit to EUR 177m in H1’25 while executes on its Value Creation Plan
Grifols will build new manufacturing site in Spain to double its plasma fractionation capacity in Europe
Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2024
Grifols’ positive fibrinogen phase 3 trial results published in The Lancet’s eClinicalMedicine
Grifols successfully completes Biotest delisting
Anne-Catherine Berner, new Grifols Chair
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.